Quantcast

Latest Fovea Stories

2012-01-27 10:25:50

In 2011 – to the consternation of women everywhere – a systematic review of randomized clinical trials showed that routine mammography was of little value to younger women at average or low risk of breast cancer. The review showed, for example, that for every 50-year-old woman whose life is prolonged by mammography, dozens are treated unnecessarily – some with harmful consequences – or treated without benefit. Hundreds are told they have breast cancer when they do...

2012-01-19 17:21:24

Age-related macular degeneration (AMD) is the most frequent cause of blindness in the Western World. A report from the University of Copenhagen and Glostrup Hospital in Denmark published today shows the number of new cases of blindness and severe visual loss in Denmark has been halved during the last ten years. The study just published in American Journal of Ophthalmology examined the records of 11,848 new cases of legal blindness. The rate of blindness from AMD fell from 522 cases per...

2011-06-10 12:25:00

Vision scientists have identified a key player in macular degeneration (MD), raising hope for a treatment for the currently incurable blinding disease. The studies reveal how light-damaged eyes invoke an out-of-control immune response, resulting in white blood cells invading the retina and leaving behind proteins that kill the light sensitive vision cells. This type of immune attack is seen in macular degeneration, which accounts for half of the vision loss cases in Australia, costing the...

1c1a75ec10ed214ef383b05c1c177c02
2011-06-09 09:08:28

Adaptive optics technology likely to spur sight-saving interventions, usher in new era of eye disease research, diagnosis and treatment Scientists today reported that the tiny light-sensing cells known as rods have been clearly and directly imaged in the living eye for the first time. Using adaptive optics (AO), the same technology astronomers use to study distant stars and galaxies, scientists can see through the murky distortion of the outer eye, revealing the eye's cellular structure with...

2011-03-16 07:10:00

ST. LOUIS, March 16, 2011 /PRNewswire/ -- ZeaVision, LLC announced that its Zeaxanthin-based nutraceutical, EyePromise Restore, has been improved with a 25% increase in Omega 3's and the addition of Vitamin D3. EyePromise Restore increases low macular pigment density, a risk factor for Age-Related Macular Degeneration (AMD), and people have an opportunity to win a bottle of EyePromise Restore at http://www.amdchallenge.com, a website designed to create awareness around AMD. EyePromise...

f7ff3a7659388f873fcc40f2555edad01
2010-07-28 10:33:25

Seahorses are helping scientists gain new understanding about how detailed vision develops "“ in research which may open a way to restore sight in people with age-related blinding diseases. Researchers at the Vision Centre have found that the seahorses' eyes share similarities with the human eye, leading to the possibility of imitating the development of the seahorse's fovea to regenerate this vital region of the eye in people with impaired vision. "The fovea is the tiny pit at the back...

2010-07-07 11:23:00

ST. LOUIS, July 7 /PRNewswire/ -- ZeaVision's EyePromise® nutraceutical products are unique science-based formulations designed to support eye health. EyePromise Restore and EyePromise Ten rapidly increase macular pigment density in the eye, minimizing many common vision challenges such as glare and night driving, bright light sensitivity, dark adaptation, and poor contrast sensitivity. Zeaxanthin is a natural macular pigment found in the eye that accumulates primarily...

2010-05-20 07:44:00

GENEVA, May 20 /PRNewswire/ -- Valensa International (Eustis, FL USA) announced the introduction of a new eye health formulation that combines the leading eye health ingredients in a single, easy-to-use product. Called Eye Pro MD, the new formulation contains carotenoids astaxanthin, lutein, and zeaxanthin and features a proprietary Omega-3/phospholipid delivery system as well as Vitamin D3. The formulation has been developed based on the results from the CARMIS clinical trial (Carotenoids...

2009-10-01 02:17:00

PARIS, Oct. 1 /PRNewswire/ -- Fovea Pharmaceuticals announced today that it has entered into a binding agreement with sanofi-aventis to sell 100% of its share to sanofi-aventis. Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to back of the eye diseases. The deal is valued to a total of euro 370M, including an immediate upfront payment and subsequent milestone payments related to the progress of the clinical...

2009-08-13 09:47:18

Three young adults who received gene therapy for a blinding eye condition remained healthy and maintained previous visual gains one year later, according to an August online report in Human Gene Therapy. One patient also noticed a visual improvement that helped her perform daily tasks, which scientists describe in an Aug. 13 letter to the editor in the New England Journal of Medicine.These findings have emerged from a phase I clinical trial supported by the National Eye Institute (NEI) at the...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related